The purpose of this study is to increase the fraction of patients, who become MRD-negative
during consolidation for the non-HR ALL group through individualized intensification of the
6MP-dosage days 30-85.
Phase:
Phase 3
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborator:
Nordic Society for Pediatric Hematology and Oncology